AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8124700 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 2.3% and 1.1% varnish
Number of subjects: 274
Study 2811065 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg (F)
Number of subjects: 9
Study 2811065 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide 500 mg (C)
Number of subjects: 9
Study 2811065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 2811065 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with spironolactone (100 mg b.i.d.) (F + S)
Number of subjects: 9
Study 2811065 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide during furosemide infusion
Number of subjects: 9
Study 780312 — intervention group
Group type: EXPERIMENTAL
Intervention: Renografin 76
Number of subjects: 58
Study 780312 — intervention group
Group type: COMPARATOR
Intervention: Isopaque 370
Number of subjects: 58
Study 30664239 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (electronic alerts combined with pharmacist support to deprescribe anticholinergics and benzodiazepines)
Number of subjects: 200
Study 30664239 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 29166987 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR) treatment, four 20-minute sessions at weekly intervals.
Number of subjects: 19
Study 29166987 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 19
Study 25912475 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 250
Study 25912475 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study 23274511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU urinary hCG
Number of subjects: 180
Study 23274511 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg recombinant hCG
Number of subjects: 180
Study 23274511 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg recombinant hCG
Number of subjects: 180
Study 22004426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 100
Study 22004426 — intervention group
Group type: COMPARATOR
Intervention: No bariatric surgery (control group)
Number of subjects: 100
Study 19596014 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 or 10 mg/kg) intravenously at weeks 0, 2, and 6, then every 8 weeks through week 46 (ACT‐1) or 22 (ACT‐2)
Number of subjects: 728
Study 19596014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 19596014 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 728
Study 16498861 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg for 14 days
Number of subjects: 100
Study 16498861 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 100
Study 14600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma clearance of (99m)Tc‐HEPIDA (Cl(Pl))
Number of subjects: 131
Study 14600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver clearance of (99m)Tc‐HEPIDA (Cl(Hp))
Number of subjects: 131
Study 14600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of individual values of both clearances with individual score of liver damage
Number of subjects: 131
Study 14600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Factorial analysis for parenchyma performance
Number of subjects: 131
Study 14600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of liver performance
Number of subjects: 131
Study 10499754 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg (1 mL) clonidine
Number of subjects: 40
Study 10499754 — intervention group
Group type: COMPARATOR
Intervention: 1 mL preservative‐free normal saline mixed with local anesthetic (7 mL 1% preservative‐free lidocaine)
Number of subjects: 40
Study 8815563 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (oral coumadin or standard intravenous heparin)
Number of subjects: 69
Study 8815563 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients
Number of subjects: 69
Study 8815563 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm patients (control group)
Number of subjects: 69
Study 1903407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 156
Study 1903407 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 156
Study 7226713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg) administered via intravenous infusion
Number of subjects: 6
Study 7226713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg) oral tablet
Number of subjects: 6
Study 7226713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg)
Number of subjects: 6
Study 28366302 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft
Number of subjects: 160
Study 26299540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed, low radiant exposure diode laser treatments
Number of subjects: 39
Study 26299540 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental radiant exposure diode laser treatments
Number of subjects: 39
Study 25336915 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 30
Study 25336915 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 10 mg
Number of subjects: 30
Study 25336915 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 20 mg
Number of subjects: 30
Study 25336915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22448936 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TENS
Number of subjects: 20
Study 22448936 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 20
Study 20214474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir suppressive therapy (400 mg twice daily)
Number of subjects: 0
Study 17878471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17878471 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study 15597186 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation with equal numbers of elements on both scales
Number of subjects: 0
Study 15597186 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of elements on the unattended scale
Number of subjects: 0
Study 15597186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower number of elements on the unattended scale
Number of subjects: 0
Study 15597186 — intervention group
Group type: EXPERIMENTAL
Intervention: Response cues blocked in Experiment 2
Number of subjects: 0
Study 12401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40
Study 12401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 12401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 12401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/midazolam
Number of subjects: 40
Study 10187877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 620
Study 10187877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 31951862 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (% of total energy intake)
Number of subjects: 23
Study 31951862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat intake (% of total energy intake)
Number of subjects: 23
Study 31951862 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute intake of ω‐3
Number of subjects: 23
Study 31951862 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute intake of vitamin D
Number of subjects: 23
Study 30890624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.1%
Number of subjects: 36
Study 30890624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28506865 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological prognostication recommendations (continue, not escalate, withdraw)
Number of subjects: 939
Study 28506865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosticated patients
Number of subjects: 939
Study 28506865 — intervention group
Group type: EXPERIMENTAL
Intervention: WLST patients
Number of subjects: 939
Study 28506865 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for care (continue, not escalate, withdraw)
Number of subjects: 939
Study 25609032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertise Flow™
Number of subjects: 46
Study 25609032 — intervention group
Group type: COMPARATOR
Intervention: Universal Dentine Sealant
Number of subjects: 46
Study 25609032 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Protect Bond
Number of subjects: 46
Study 25609032 — intervention group
Group type: COMPARATOR
Intervention: Flor-Opal® Varnish
Number of subjects: 46
Study 23239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Total atrial conduction time (PA‐TDI duration)
Number of subjects: 128
Study 23239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 128
Study 23239219 — intervention group
Group type: EXPERIMENTAL
Intervention: LA maximum volume
Number of subjects: 128
Study 23239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged PA‐TDI duration
Number of subjects: 128
Study 21658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 U aXa o.d.
Number of subjects: 1239
Study 21658750 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU t.i.d.
Number of subjects: 1239
Study 21658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of proximal DVT, symptomatic non-fatal PE and VTE related death
Number of subjects: 1239
Study 21658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1239
Study 18697887 — intervention group
Group type: EXPERIMENTAL
Intervention: risk information leaflet
Number of subjects: 3185
Study 18697887 — intervention group
Group type: EXPERIMENTAL
Intervention: risk and screening information leaflet
Number of subjects: 3185
Study 18697887 — intervention group
Group type: COMPARATOR
Intervention: control‐‐no information
Number of subjects: 3185
Study 21746765 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 465
Study 21746765 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 465
Study 21746765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aliskiren and losartan
Number of subjects: 465
Study 16145378 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of intravesical BCG (81 mg)
Number of subjects: 155
Study 16145378 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased dose of intravesical BCG (27 mg)
Number of subjects: 155
Study 11793426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg) with levodopa/carbidopa (100/125 mg)
Number of subjects: 12
Study 11793426 — intervention group
Group type: COMPARATOR
Intervention: Placebo with levodopa/carbidopa (100/125 mg)
Number of subjects: 12
Study 9519342 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins (VLDL, IDL, apolipoprotein B-containing lipoprotein particles, apolipoprotein C-III)
Number of subjects: 0
Study 9519342 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins
Number of subjects: 0
Study 9519342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesteryl-ester rich lipoproteins (LDL cholesterol)
Number of subjects: 0
Study 7977607 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000-IU dose of vitamin A
Number of subjects: 114
Study 7977607 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000-IU dose of vitamin A
Number of subjects: 114
Study 3184215 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin (Clind/Gent)
Number of subjects: 147
Study 3184215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (Mezlo)
Number of subjects: 147
Study 11514818 — intervention group
Group type: EXPERIMENTAL
Intervention: Side posture manipulation
Number of subjects: 0
Study 11514818 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (mostly flexion distraction)
Number of subjects: 0
Study 11514818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 0
Study 30617480 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective measurements based on modified RECIST criteria
Number of subjects: 41
Study 30617480 — intervention group
Group type: COMPARATOR
Intervention: Primary measurements by clinical radiologists
Number of subjects: 41
Study 30617480 — intervention group
Group type: COMPARATOR
Intervention: Primary measurements
Number of subjects: 41
Study 30617480 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary and retrospective measurements
Number of subjects: 41
Study 30535865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile CT examination workflow (study group)
Number of subjects: 98
Study 30535865 — intervention group
Group type: COMPARATOR
Intervention: Conventional stationary workflow (reference group)
Number of subjects: 98
Study 26584960 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 158
Study 26584960 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 158
Study 25007692 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 64
Study 25007692 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FOB)
Number of subjects: 64
Study 22343419 — intervention group
Group type: EXPERIMENTAL
Intervention: Realsil (RA)
Number of subjects: 179
Study 22343419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 179
Study 21431257 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged healing (Group A)
Number of subjects: 40
Study 21431257 — intervention group
Group type: COMPARATOR
Intervention: Non-submerged healing (Group B)
Number of subjects: 40
Study 21431257 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 17885543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 0
Study 17885543 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 17885543 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard vs ACE inhibitors
Number of subjects: 0
Study 15166882 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radioiodine (100 mCi iodine-131)
Number of subjects: 142
Study 12237621 — intervention group
Group type: EXPERIMENTAL
Intervention: Levormeloxifene 0.5 mg daily
Number of subjects: 2924
Study 12237621 — intervention group
Group type: EXPERIMENTAL
Intervention: Levormeloxifene 1.25 mg daily
Number of subjects: 2924
Study 12237621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2924
Study 9665228 — intervention group
Group type: EXPERIMENTAL
Intervention: HERS cohort
Number of subjects: 2763
Study 7865643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran supplementation (12 g/day)
Number of subjects: 80
Study 7865643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7865643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran supplementation
Number of subjects: 80
Study 2717904 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% (w/v) PGE1 solution in saline injected under the mucoperiosteum palatal to the test tooth
Number of subjects: 5
Study 2717904 — intervention group
Group type: COMPARATOR
Intervention: Saline injected palatal to the contralateral control tooth
Number of subjects: 5
Study 31654125 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) for 8 weeks
Number of subjects: 48
Study 31654125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific exercises)
Number of subjects: 48
Study 30455261 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 0
Study 28974265 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias training
Number of subjects: 182
Study 28974265 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach bias training
Number of subjects: 182
Study 28974265 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of attentional bias training
Number of subjects: 182
Study 28974265 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of approach bias training
Number of subjects: 182
Study 28974265 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (attentional and approach bias training, placebo versions)
Number of subjects: 182
Study 26569470 — intervention group
Group type: COMPARATOR
Intervention: Standard packaging alone
Number of subjects: 118
Study 26569470 — intervention group
Group type: COMPARATOR
Intervention: Standard packaging + pre-existing warning label
Number of subjects: 118
Study 26569470 — intervention group
Group type: COMPARATOR
Intervention: Standard packaging + large customized warning label
Number of subjects: 118
Study 24660584 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sishen Wan (treatment group A)
Number of subjects: 240
Study 24660584 — intervention group
Group type: COMPARATOR
Intervention: Placebo, Chao Maiya (control group B)
Number of subjects: 240
Study 21601513 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual pain
Number of subjects: 15
Study 21601513 — intervention group
Group type: COMPARATOR
Intervention: Neutral stimulus
Number of subjects: 15
Study 21601513 — intervention group
Group type: COMPARATOR
Intervention: Actual heat
Number of subjects: 15
Study 21601513 — intervention group
Group type: COMPARATOR
Intervention: Expected heat
Number of subjects: 15
Study 21601513 — intervention group
Group type: COMPARATOR
Intervention: Expected pain
Number of subjects: 15
Study 18349203 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200
Study 16473497 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 13
Study 16473497 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric glucose
Number of subjects: 13
Study 12648685 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day
Number of subjects: 261
Study 12648685 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 261
Study 10365011 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 micrograms kg‐1
Number of subjects: 80
Study 10365011 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 micrograms kg‐1
Number of subjects: 80
Study 10365011 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.25 micrograms kg‐1
Number of subjects: 80
Study 10365011 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 8654642 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU human GH
Number of subjects: 22
Study 8654642 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 IU human GH
Number of subjects: 22
Study 8654642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2068563 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg three times daily
Number of subjects: 20
Study 2068563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6185109 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐course, high fractional dose radiation therapy (6,000 to 7,000 rad in six to seven weeks)
Number of subjects: 64
Study 6185109 — intervention group
Group type: COMPARATOR
Intervention: Conventional protracted radiation schedule (4,000 to 4,800 rad in two to three weeks)
Number of subjects: 64
Study 30409049 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred ADL intervention
Number of subjects: 280
Study 30409049 — intervention group
Group type: COMPARATOR
Intervention: Usual ADL interventions
Number of subjects: 280
Study 30570087 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture at energy balance points and points indicated for pain treatment.
Number of subjects: 31
Study 30570087 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with fixed placebo points.
Number of subjects: 31
Study 26817503 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and multivitamin (Zn+MV) supplementation
Number of subjects: 2400
Study 26817503 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-only supplementation
Number of subjects: 2400
Study 26817503 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 2400
Study 26817503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 24642984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 µg)
Number of subjects: 48
Study 24642984 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estradiol (50 µg for 7 days)
Number of subjects: 48
Study 21972268 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 28
Study 21972268 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 28
Study 19171852 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3405
Study 19171852 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 3405
Study 19171852 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3405
Study 19171852 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin with or without IIb/IIIa inhibitors
Number of subjects: 3405
Study 17254485 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization for gastric fundus varices combined with endoscopic variceal ligation (EVL) for esophageal varices
Number of subjects: 172
Study 17254485 — intervention group
Group type: COMPARATOR
Intervention: Embolization for gastric fundus varices
Number of subjects: 172
Study 16342093 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly subcutaneously
Number of subjects: 26
Study 12505222 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50
Study 12505222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50